ESC Congress 2017

26 - 30 August 2017, Barcelona - Spain

Session Details

Poster session 7 : Prevention general
Tue 29 Aug 14:00 - 18:00 Miscellaneous Poster Session Posters - Poster Area
Learning Objectives: Posters are on display from 14:00 – 18:00. Presenters will be by their poster during the coffee break from 15:30 and 16:30 for posters viewing time

Abstract Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Related documents
14:00P6203Major adverse cardiovascular events (MACE) are reduced in testosterone-treated vs. untreated hypogonadal men: real-life evidence from a controlled registry studyFarid SAAD (Berlin, Germany)
14:00P6204Enhanced cardiovascular susceptibility to air pollution: A 4 years echocardiographic study of pulmonary circulation.Jean-Francois ARGACHA (Jette, Belgium)
14:00P6205Systemic inflammatory response in chronic venous disorders and their clinical relevance in the general population.Natalie ARNOLD (Mainz, Germany)
14:00P6206The hemoglobin A1C and creatinine are associated with coronary calcium score for female but not male in a general low risk populationJia Ru WU (Taipei, Taiwan ROC)
14:00P6207ABCA1 gene polymorphism InsG319 prevents the development of impaired glucose tolerance in young and middle-aged womenSvetlana BOLDUEVA (Saint-Petersburg, Russian Federation)
14:00P6208Andexanet alfa reduces betrixaban-induced blood loss in a rabbit liver laceration model of acute bleeding.Pamela CONLEY (South San Francsico, United States of America)
14:00P6209Perinatal outcome of fetus with prenatal diagnosed congenital heart defects, results of a cohort study from chinaYanji QU (Guangzhou, China People's Republic of)
14:00P6210Relation of renal dysfunction to quality of anticoagulation control in patients with atrial fibrillation: The FANTASIIA registryMaria Asuncion ESTEVE PASTOR (Elche, Spain)
14:00P6212Target organ damage in patients in the primary care with or without arterial hypertension, data from the IBERICAN study.Rafael Carlos VIDAL PEREZ (Lugo, Spain)
14:00P6213Differences in recommendations and associated level of evidence for statins in primary prevention of CVD according to the ACC/AHA 2013, CCS 2016, ESC 2016, and USPSTF 2016 clinical practice guidelinesMaarten J G LEENING (Rotterdam, Netherlands)
14:00P6214Genetic risk score, family history of coronary artery disease and cardiovascular risk factors.Andreia PEREIRA (Lisboa, Portugal)
14:00P6215Poor sleep and cardiovascular disease: different pattern of sleep disturbance in ischemic heart disease and strokeNobuo SASAKI (Hiroshima, Japan)
14:00P6216Assessing 10-year cardiovascular disease risk in malaysians with type 2 diabetes mellitus: framingham risk score versus UKPDSSheng Qian YEW (Cheras, Malaysia)
14:00P6217Myocardial damage markers can risk-stratify aortic aneurysm patients with coronary artery diseaseKen WATANABE (Sagae, Japan)
14:00P6218Serum levels of Mac-2 binding protein reflect silent atherosclerosisTomonori SUGIURA (Nagoya, Japan)
14:00P6219Impact of lifestyle interventions on body weight and mortality: a meta-analysis of randomized controlled trials.Navneet SINGH (Auckland, New Zealand)
14:00P6220The creatinine to uromodulin ratio in serum predicts major cardiovascular events independently from the presence of type 2 diabetesChristoph Hubert SAELY (Feldkirch, Austria)
14:00P6221Prognostic performance of APRIL, a TNF alpha family protein, in acutely breathless patients.Chris PEMBERTON (Christchurch, New Zealand)
14:00P6222Serum uromodulin predicts mortality independently from the presence of type 2 diabetesChristoph Hubert SAELY (Feldkirch, Austria)
14:00P6223Restless legs syndrome is an independent risk factor for heart failure with preserved ejection fractionZoe HEIS (Wausau, United States of America)
14:00P6224Comparison of high-sensitivity cardiac troponin I and T for the prediction of cardiac complications after non-cardiac surgeryDanielle GUALANDRO (Sao Paulo, Brazil)
14:00P6225Trajectories of inflammation biomarker associated with all-cause and cardiovascular disease mortality in older adults: evidence from ELSACamille LASSALE (London, United Kingdom)
14:00P6226Differences in markers of cardiovascular prognosis between patients with ST segment elevation and non ST segment elevation myocardial infarction.George LAZAROS (Athens, Greece)
14:00P6227Prognostic impact of soluble p-selectin on long-term adverse cardiovascular outcome in patients with acute and stable coronary artery diseaseMaximilian TSCHARRE (Vienna, Austria)
14:00P6229TACE gene expression and soluble receptors TNFRI and TNFRII levels identifies very high risk cardiovascular patientsMelody CHEMALY (Derry, United Kingdom)
14:00P6230Measurement assay and inflammation influence the predictive role of levels of proprotein convertase subtilisin/kexin type 9 for cardiovascular events: a meta-analysis and a meta-regression analysis Dimitrios TERENTES-PRINTZIOS (Athens, Greece)
14:00P6231Platelet-to-lymphocyte ratio is a marker of multivessel coronary artery disease in high risk older patientsIssada TRAKARNWIJITR (Lavington, Australia)